Current:Home > InvestAn experimental Alzheimer's drug outperforms one just approved by the FDA-DB Wealth Institute B2 Expert Reviews
An experimental Alzheimer's drug outperforms one just approved by the FDA
View Date:2024-12-24 00:00:22
Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking.
In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%, scientists reported at the Alzheimer's Association International Conference in Amsterdam.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
"This is the biggest effect that's ever been seen in an Alzheimer's trial for a disease-modifying drug," says Dr. Daniel Skrovonsky, director of research and development at Eli Lilly, which makes donanemab.
The company has submitted the results to the Food and Drug Administration and expects a decision by the end of the year.
But experts caution that donanemab is no cure, and that its benefit amounts to only about a seven-month delay in the loss of memory and thinking.
"I do think that will make a difference to people," says Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston. "But we have to do better."
Early treatment is key
Donanemab, like Leqembi, is a monoclonal antibody designed to remove a substance called beta-amyloid from the brain. Beta-amyloid tends to form sticky plaques in the brains of people with Alzheimer's.
The donanemab study focused on people whose brain scans showed plaques and other changes associated with early Alzheimer's. They had only mild cognitive symptoms.
Even within that group, though, people with more advanced disease saw less benefit from the drug.
"What we saw is that the ability to slow disease progression is strongest if you catch this disease earlier," Skrovonsky says.
The study also suggests that patients may not need monthly intravenous infusions of donanemab for life.
Patients were taken off the drug once the plaques in their brains were mostly gone, usually within a year. The plaques did not reappear during the 18-month study, and the benefit to memory and thinking continued.
That appears to give donanemab an edge over Leqembi, which requires ongoing treatment. But it's still not clear whether donanemab's benefits will persist for years after treatment ends.
"I imagine in the future we'll have this initiation phase where we knock down plaque and then we'll have maintenance therapy," Sperling says.
Both donanemab and Leqembi can cause dangerous swelling or bleeding in the brain.
In the donanemab study, brain scans revealed this side effect in about 25% of patients. About 6% had symptoms, like headache, nausea, and confusion. Three patients died.
A new era for Alzheimer's treatment?
The results with both donanemab and Leqembi provide strong evidence that removing amyloid from the brain can slow down Alzheimer's. That approach, known as the amyloid hypothesis, had been in doubt after dozens of other amyloid drugs failed to help patients.
One reason for the recent success is earlier treatment, Sperling says. Instead of treating patients who've already sustained significant brain damage from Alzheimer's, researchers have focused on people whose brains are still relatively healthy.
Another factor is the way researchers are approaching treatment, Sperling says.
"We've learned to be more aggressive with dosing," she says, which quickly reduces amyloid to very low levels in the brain.
But scientists still aren't sure which forms of amyloid offer the best target.
Single amyloid molecules appear to be harmless. But scientists have learned that when these molecules begin to clump together, they can take on forms that are toxic. Eventually, these clumps end up in plaques between brain cells.
"There's been a debate in our field for 30 years now about whether the plaques themselves are causing the problem," Sperling says. And the results with donanemab and leqembi are unlikely to end that debate.
Donanemab is designed to target plaques specifically. Leqembi is designed to target other forms of amyloid, though it also removes plaques.
Yet both drugs appear to slow down the loss of memory and thinking, in patients with early Alzheimer's.
A study Sperling is involved in could help answer the amyloid question by treating people who still have very little plaque in their brains.
"If we see benefit even at that stage," Sperling says, "one might argue it's not just plaque" eroding memory and thinking.
veryGood! (2)
Related
- Rita Ora pays tribute to Liam Payne at MTV Europe Music Awards: 'He brought so much joy'
- Four students arrested and others are suspended following protest at Vanderbilt University
- Elizabeth Chambers Addresses Armie Hammer Scandal in Grand Cayman: Secrets in Paradise Trailer
- Cute College Graduation Outfit Ideas That’ll Look Good Under Any Cap & Gown
- Don't Miss Cameron Diaz's Return to the Big Screen Alongside Jamie Foxx in Back in Action Trailer
- This social media network set the stage for Jan. 6, then was taken offline. Now it's back
- Rebel Wilson Shares She Lost Her Virginity at Age 35
- Italy expands controversial program to take mafia children from their families before they become criminals
- Man jailed after Tuskegee University shooting says he fired his gun, but denies shooting at anyone
- Underage teen workers did 'oppressive child labor' for Tennessee parts supplier, feds say
Ranking
- Why have wildfires been erupting across the East Coast this fall?
- Beyoncé called out country music at CMAs. With 'Act II,' she's doing it again.
- Applications for US unemployment benefits dip to 210,000 in strong job market
- To combat bullying and extremism, Air Force Academy turns to social media sleuthing
- Kennesaw State football coach Brian Bohannon steps down after 10 seasons amid first year in FBS
- Home Depot acquires SRS Distribution in $18 billion purchase to attract more pro customers
- Subaru recalls nearly 119,000 vehicles over air bag problem
- Avril Lavigne, Katy Perry, Meryl Streep and More Stars Appearing at iHeartRadio Music Awards
Recommendation
-
In an AP interview, the next Los Angeles DA says he’ll go after low-level nonviolent crimes
-
Universities of Wisconsin president proposes 3.75% tuition increase
-
‘Murder in progress': Police tried to spare attacker’s life as they saved woman from assault
-
US economic growth for last quarter is revised up slightly to a healthy 3.4% annual rate
-
Congress heard more testimony about UFOs: Here are the biggest revelations
-
Sean Diddy Combs' Alleged Drug Mule Arrested at Airport Amid Home Raids
-
Punxsutawney Phil, the spring-predicting groundhog, and wife Phyliss are parents of 2 babies
-
Down ACC? Think again. Conference reminding all it's still the king of March Madness.